Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 43% Improvement Relative Risk Recovery time 15% Viral clearance, day 14 5% primary Viral clearance, day 7 3% Manomaipiboon et al. NCT05076253 Ivermectin RCT EARLY Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 72 patients in Thailand (October - December 2021) Improved recovery with ivermectin (not stat. sig., p=0.26) Manomaipiboon et al., Trials, doi:10.1186/s13063-022-06649-3 Favors ivermectin Favors control
Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial
Manomaipiboon et al., Trials, doi:10.1186/s13063-022-06649-3 (date from earlier preprint), NCT05076253 (history)
Manomaipiboon et al., Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized,.., Trials, doi:10.1186/s13063-022-06649-3 (date from earlier preprint), NCT05076253
Feb 2022   Source   PDF  
  All Studies   Meta
Small RCT with 72 low-risk patients in Thailand, showing improved recovery with ivermectin, without statistical significance. All patients recovered and there was no escalation of care in either group. There were no adverse events.
risk of no recovery, 43.5% lower, RR 0.57, p = 0.26, treatment 3 of 36 (8.3%), control 6 of 36 (16.7%), NNT 12, adjusted per study, odds ratio converted to relative risk, resolution of symptoms, Table S2, day 28.
recovery time, 15.3% lower, RR 0.85, p = 0.56, treatment 36, control 36, inverted to make RR<1 favor treatment, time to resolution of symptoms.
risk of no viral clearance, 5.0% lower, RR 0.95, p = 1.00, treatment 19 of 36 (52.8%), control 20 of 36 (55.6%), NNT 36, day 14, primary outcome.
risk of no viral clearance, 3.3% lower, RR 0.97, p = 1.00, treatment 29 of 36 (80.6%), control 30 of 36 (83.3%), NNT 36, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Manomaipiboon et al., 2 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Thailand, peer-reviewed, mean age 48.6, 8 authors, study period 10 October, 2021 - 15 December, 2021, dosage 12mg days 1-5, trial NCT05076253 (history).
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial Anan Manomaipiboon Navamindradhiraj University Kitisak Pholtawornkulchai Navamindradhiraj University Sujaree Pupipatpab Navamindradhiraj University Swangjit Suraamornkul Navamindradhiraj University Jakravoot Maneerit Navamindradhiraj University Wiroj Ruksakul Navamindradhiraj University Uraporn Phumisantiphong Navamindradhiraj University Thananda Trakarnvanich (  ) Navamindradhiraj University Research Article Keywords: Efficacy, Ivermectin, COVID-19, Randomized-controlled trial, SARS-CoV-2, RT-PCR Posted Date: February 2nd, 2022 DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/16 Abstract The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for therapeutic opportunities to overcome this pandemic. Ivermectin is an antiparasitic drug that has shown to be effective against various agents, including SARS-CoV-2, and is under extensive research in clinical trials. In this randomized, double-blind, placebo-controlled trial among adult hospitalized patients with mild-to-moderate COVID-19, 72 patients (mean age 48.57 ± 14.80 years) were randomly assigned to either the ivermectin (n=36) or placebo (n=36) group, along with receiving standard care. The primary outcomes were a negative reverse transcription polymerase chain reaction (RT-PCR) result at day 7 and 14 of enrolment. The secondary outcomes were duration of hospitalization, frequency of clinical worsening, survival on day 28, and adverse events. At day 7 and 14, a negative RT-PCR result was not significantly different between the two groups. The other secondary outcomes were reported to be comparable. However, the time to resolution of many symptoms were shorter in the ivermectin group, albeit not significantly. No adverse events were reported. In conclusion, early symptomatic recovery was observed with no side effects after treatment with ivermectin and standard care in mild-to-moderate COVID-19 patients.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop